A citation-based method for searching scientific literature

Elena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, Marta Rita Reforgiato, Isabella Leone, Paola Rafaniello Raviele, Elisabetta Munzone, Roswitha Kammler, Patrick Neven, Erika Hitre, Guy Jerusalem, Edda Simoncini, Andrea Gombos, Ines Deleu, Per Karlsson, Stefan Aebi, Jacquie Chirgwin, Vincenzo Di Lauro, Alastair Thompson, Marie-Pascale Graas, Matthew Barber, Christel Fontaine, Sibylle Loibl, Joaquín Gavilá, Katsumasa Kuroi, Bettina Müller, Seamus O'Reilly, Angelo Di Leo, Aron Goldhirsch, Giuseppe Viale, Massimo Barberis, Meredith M Regan, Marco Colleoni. Clin Cancer Res 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.
Martin Filipits, Peter Dubsky, Margaretha Rudas, Richard Greil, Marija Balic, Zsuzsanna Bago-Horvath, Christian F Singer, Dominik Hlauschek, Krystal Brown, Ryan Bernhisel,[...]. Clin Cancer Res 2019
20
100

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Beat Thürlimann, Aparna Keshaviah, Alan S Coates, Henning Mouridsen, Louis Mauriac, John F Forbes, Robert Paridaens, Monica Castiglione-Gertsch, Richard D Gelber, Manuela Rabaglio,[...]. N Engl J Med 2005
100

Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index.
Janghee Lee, Chihwan Cha, Sung Gwe Ahn, Dooreh Kim, Soeun Park, Soong June Bae, Jeeye Kim, Hyung Seok Park, Seho Park, Seung Il Kim,[...]. Sci Rep 2020
5
100

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Hongchao Pan, Richard Gray, Jeremy Braybrooke, Christina Davies, Carolyn Taylor, Paul McGale, Richard Peto, Kathleen I Pritchard, Jonas Bergh, Mitch Dowsett,[...]. N Engl J Med 2017
452
100

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Jack Cuzick, Ivana Sestak, Michael Baum, Aman Buzdar, Anthony Howell, Mitch Dowsett, John F Forbes. Lancet Oncol 2010
544
100

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Hiroko Yamashita, Akiko Ogiya, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Tomofumi Osako, Masato Takahashi, Yumi Endo, Mitsuchika Hosoda,[...]. Breast Cancer 2016
21
100

Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Shuzhen Liu, Stephen K Chia, Erika Mehl, Samuel Leung, Ashish Rajput, Maggie C U Cheang, Torsten O Nielsen. Breast Cancer Res Treat 2010
83
100

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Erik J Blok, Judith R Kroep, Elma Meershoek-Klein Kranenbarg, Marjolijn Duijm-de Carpentier, Hein Putter, Joan van den Bosch, Eduard Maartense, A Elise van Leeuwen-Stok, Gerrit-Jan Liefers, Johan W R Nortier,[...]. J Natl Cancer Inst 2018
58
100



Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Eitan Amir, Bostjan Seruga, Saroj Niraula, Lindsay Carlsson, Alberto Ocaña. J Natl Cancer Inst 2011
331
100

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martin, Zhi Min Shao, Qing Yuan Zhang, Jorge Luis Martinez Rodriguez, Mario Campone, Erika Hamilton,[...]. J Clin Oncol 2020
67
100

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
C Davies, J Godwin, R Gray, M Clarke, D Cutter, S Darby, P McGale, H C Pan, C Taylor, Y C Wang,[...]. Lancet 2011
100

Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.
Caitlin C Murphy, L Kay Bartholomew, Melissa Y Carpentier, Shirley M Bluethmann, Sally W Vernon. Breast Cancer Res Treat 2012
342
100

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.
Barbara Pistilli, Angelo Paci, Arlindo R Ferreira, Antonio Di Meglio, Vianney Poinsignon, Aurelie Bardet, Gwenn Menvielle, Agnes Dumas, Sandrine Pinto, Sarah Dauchy,[...]. J Clin Oncol 2020
21
100


Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
F Bertucci, P Finetti, H Roche, J M Le Doussal, L Marisa, A L Martin, M Lacroix-Triki, C Blanc-Fournier, J Jacquemier, H Peyro-Saint-Paul,[...]. Ann Oncol 2013
23
100

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Raimund Jakesz, Richard Greil, Michael Gnant, Marianne Schmid, Werner Kwasny, Ernst Kubista, Brigitte Mlineritsch, Christoph Tausch, Michael Stierer, Friedrich Hofbauer,[...]. J Natl Cancer Inst 2007
198
100

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Paul E Goss, James N Ingle, Silvana Martino, Nicholas J Robert, Hyman B Muss, Martine J Piccart, Monica Castiglione, Dongsheng Tu, Lois E Shepherd, Kathleen I Pritchard,[...]. N Engl J Med 2003
100

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, Jon Godwin, Richard Gray, Rodrigo Arriagada, Vinod Raina, Mirta Abraham, Victor Hugo Medeiros Alencar, Atef Badran, Xavier Bonfill,[...]. Lancet 2013
100

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
N Zdenkowski, J F Forbes, F M Boyle, G Kannourakis, P G Gill, E Bayliss, C Saunders, S Della-Fiorentina, N Kling, I Campbell,[...]. Ann Oncol 2016
8
100


Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Vivianne C G Tjan-Heijnen, Irene E G van Hellemond, Petronella G M Peer, Astrid C P Swinkels, Carolien H Smorenburg, Maurice J C van der Sangen, Judith R Kroep, Hiltje De Graaf, Aafke H Honkoop, Frans L G Erdkamp,[...]. Lancet Oncol 2017
48
100

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ivana Sestak, Richard Buus, Jack Cuzick, Peter Dubsky, Ralf Kronenwett, Carsten Denkert, Sean Ferree, Dennis Sgroi, Catherine Schnabel, Frederick L Baehner,[...]. JAMA Oncol 2018
122
100


Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.
Bernhard C Pestalozzi, David Zahrieh, Elizabeth Mallon, Barry A Gusterson, Karen N Price, Richard D Gelber, Stig B Holmberg, Jurij Lindtner, Raymond Snyder, Beat Thürlimann,[...]. J Clin Oncol 2008
240
100

Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence.
Fabio Conforti, Laura Pala, Eleonora Pagan, Giuseppe Viale, Vincenzo Bagnardi, Giulia Peruzzotti, Tommaso De Pas, Nadia Bianco, Rossella Graffeo, Elena Guerini Rocco,[...]. Breast Cancer Res 2019
4
100

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Richard Buus, Ivana Sestak, Ralf Kronenwett, Carsten Denkert, Peter Dubsky, Kristin Krappmann, Marsel Scheer, Christoph Petry, Jack Cuzick, Mitch Dowsett. J Natl Cancer Inst 2016
120
100

Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.
Yi Zhang, Catherine A Schnabel, Brock E Schroeder, Piiha-Lotta Jerevall, Rachel C Jankowitz, Tommy Fornander, Olle Stål, Adam M Brufsky, Dennis Sgroi, Mark G Erlander. Clin Cancer Res 2013
121
100

The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Martin Filipits, Torsten O Nielsen, Margaretha Rudas, Richard Greil, Herbert Stöger, Raimund Jakesz, Zsuzsanna Bago-Horvath, Otto Dietze, Peter Regitnig, Christine Gruber-Rossipal,[...]. Clin Cancer Res 2014
117
100

Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
Hadar Goldvaser, Tristan A Barnes, Boštjan Šeruga, David W Cescon, Alberto Ocaña, Domen Ribnikar, Eitan Amir. J Natl Cancer Inst 2018
67
100

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Paul E Goss, James N Ingle, Silvana Martino, Nicholas J Robert, Hyman B Muss, Martine J Piccart, Monica Castiglione, Dongsheng Tu, Lois E Shepherd, Kathleen I Pritchard,[...]. J Natl Cancer Inst 2005
771
100

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
Eleftherios P Mamounas, Jong-Hyeon Jeong, D Lawrence Wickerham, Roy E Smith, Patricia A Ganz, Stephanie R Land, Andrea Eisen, Louis Fehrenbacher, William B Farrar, James N Atkins,[...]. J Clin Oncol 2008
216
100

Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
Dennis C Sgroi, Erin Carney, Elizabeth Zarrella, Lauren Steffel, Shemeica N Binns, Dianne M Finkelstein, Jackie Szymonifka, Atul K Bhan, Lois E Shepherd, Yi Zhang,[...]. J Natl Cancer Inst 2013
102
100

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, Lisa M McShane, Fabrice Andre, Deborah E Collyar, Ana M Gonzalez-Angulo, Elizabeth H Hammond, Nicole M Kuderer, Minetta C Liu, Robert G Mennel,[...]. J Clin Oncol 2016
447
100

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, Elena Lopez-Knowles, Kalvinder Sidhu, Anita K Dunbier, J Wayne Cowens, Sean Ferree, James Storhoff, Carl Schaper, Jack Cuzick. J Clin Oncol 2013
371
100

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Mitch Dowsett, Ivana Sestak, Meredith M Regan, Andrew Dodson, Giuseppe Viale, Beat Thürlimann, Marco Colleoni, Jack Cuzick. J Clin Oncol 2018
51
100

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
P Dubsky, J C Brase, R Jakesz, M Rudas, C F Singer, R Greil, O Dietze, I Luisser, E Klug, R Sedivy,[...]. Br J Cancer 2013
185
100


Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
A R Ferreira, A Di Meglio, B Pistilli, A S Gbenou, M El-Mouhebb, S Dauchy, C Charles, F Joly, S Everhard, M Lambertini,[...]. Ann Oncol 2019
34
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.